BioLife TV

Michael Dunne

MD, Pfizer Vice President, Worldwide Therapeutic Area Development for Infectious Diseases

Dr Dunne comments on the struggle to conquer infectious diseases.

Mitchell Cohen

MD, Director, Coordinating Center for Infectious Diseases, CDC

Dr Cohen comments on the recent phenomenon of community outbreaks of MRSA.

Sir Tom McKillop

Former Chief Executive, AstraZeneca PLC;

Now, Group Chairman, The Royal Bank of Scotland

Prior to his departure from AstraZeneca in 2005, Sir McKillop commented on the role of Industry in the battle to conquer Infectious Disease.

Bernard Kouchner

MD, Co-founder, Doctors Without Borders; Former French Health Minister

Dr Kouchner urges us to bridge the gap of human differences (race, wealth disparity, etc.)

Kul Chandra Gautam

Deputy Executive Director, UNICEF

Mr Gautam comments on the great successes of Immunization in the fight against Infectious Disease.

Kofi A. Annan

Secretary-General of the United Nations

Mr Annan comments on access to anti-retroviral therapy and prevention services in low- and middle-income countries.

George R. Siber

MD, Executive Vice President and Chief Science Officer, Wyeth Vaccines Research

Jean Stephenne

President and General Manager, GlaxoSmithKline Biologicals

Dr Siber and Mr Stephenne comment on tiered-pricing as a means of making drugs available in developing countries.

Klaus Plate, CEO Technologiepark Heidelberg

29 january 2008, Brussels.
What does CEBR do ?

Descartes Prize 2008 : Professor Pascale Cossart

Excellence in European scientific collaborative research for the Virlis Project. Professor Pascale Cossart, from the Institut Pasteur in Paris, is the coordinator of the VIRLIS project.

Listeria monocytogenes is a bacterium responsible for one of the most severe food borne infections. However, it was not actually recognised as a food-borne pathogen until the mid-eighties. Today, the bacterium is one of the most studied organisms in infection biology and is a reference model for infectious diseases in general. This is largely thanks to the extensive research on Listeria undertaken over more than ten years by the European research consortium VIRLIS. The consortium involves eight research groups from three European countries (France (2), Germany (3) and Spain (3)) and has been at the forefront of major advances in the study of the molecular and cellular basis for the virulence of this bacterial pathogen. Professor Pascale Cossart, from the Institut Pasteur in Paris, is the coordinator of the VIRLIS project.

Janez Potocnik European Commissioner for Science and Research

Opening press conference on Transport Research Arena

Ljubljana opening ceremony

Transport Research Arena Europe 2008 (TRA 2008)

THE INNOVATIVE MEDICINES INITIATIVE (IMI)

IMI objectives, milestones and deliverables

The overall goal of the Innovative Medicines Initiative (IMI) is to re-invigorate the European bio-pharmaceutical sector and to make Europe more attractive for private research and development (R&D) investment in this sector.

TxCell Controlled Immunity

Inflamation and Regulation on Chronic Inflamamation : multiple sclerosis

Interview with EuropaBio Secretary General Willy De Greef

The first interview with the new Secretary General of EuropaBio - Catch a glimpse of what's in store for the European Association for BioIndustries.

SuppreMol

Unlocking the therapeutic potential of Fc-Receptors in autoimmune diseases

Feeding the masses

Biotechnology for the small scale farmer

Mr. John Hodgson

Director, Critical I. « How healthy is Europe's biotech ? What are the main headlines from the Critical I study published today ? ». « How does chronic under-funding affect economic competitiveness of European life sciences ? »

Dr. Andrea Rappagliosi

Vice President, Health Policy & Governmental Relations, Serono. Europabio Executive Committee Member. « If you needed to identify the root cause / the one single issue that should occupy the Commission for healthcare, what would that be ? So how do we address this issue ? »

Dr. Bernward Garthoff

President of the German BioIndustries Association (DIB). Chair of EuropaBio's Agri-food Council. « Is the Agri-Food sector making progress and what are you expecting from EU policy makers ? »

Mr. John HOLLOWAY

Director Investments, European Investment Fund (EIF). « How can private investors with government support produce biotechnology winners ? »

Dr. Johan VANHEMELRIJCK

Secretary General, EuropaBio. « There is a lot of new policies being advocated by EuropaBio Council's. What is EuropaBio doing with all these policies ? ». « We heard from Professor Debackhere about the proliferation of life science and biotechnology patents crossing into many other fields of activity for example bio-nano, bioinformatics, what does this mean for policy makers and regulators - are we equipped to deal with this convergence ? »

Mr. Iain GILLESPIE

Head of the Biotechnology Division, OECD. « Can bioscience underpin economic strategies ? »

Prof. Dr. Marc VAN MONTAGU

Chairman International Plant Biotechnology Organisation (IPBO) Gent University and President of the European Federation of Biotechnology. Marc Van Montagu is the inventor of the technology to create genetically modified (GM) plants and produced the first GM plant in Europe.. « What Europe should do to catch up with its worldwide competitors in agbiotech ? »

Dr. Hans KAST

President & CEO, BASF Plant. Science and Chairman of EuropaBio. « What has the biotech industry achieved, where is it heading and what can we expect over the next decade ? »

Mr. Michael GRIFFITH

Chair of the European Platform for Patients Organisations, Science and Industry (EPPOSI). « Can the model for rare diseases be exported to make changes in the way healthcare systems and drug developments work ? »

Lord Dick TAVERNE

House of Lords (UK). « Why must the EU not reject genetic modification ? »

Ms. Aisling BURNAND

Chief Executive Officer, BioIndustry Association, UK. Chair of EuropaBio's National Associations Council. « The UK is leading the biotech sector in Europe, how does this measure up against other nations ? The benchmark for Europe is the US, where we see a major gap, what is Europe doing wrong ? »

Dr. Philippe ARCHINARD

Chief Executive Officer, Transgene. Newly elected Chair of EuropaBio's Emerging Enterprise Councils. « Today's figures showed that biotech is chronically under-funded, how is the Emerging Enterprises Council going to tackle this ? »

Mr. Pierre ERWES

Chief Executive Officer, Biovision. « Announcing Biovision 2007 »

Dr. Hans KAST

President & CEO, BASF Plant Science and Chairman of EuropaBio. « What kind of priorities have the members given to EuropaBio for the next year ? »

Mr. Robert GOEBBELS

Member of the European Parliament. « Is the European Parliament ready to support the industrial development of biotechnologies in Europe ? »

EuropaBio's Open Day

Welcome & Keynote Speech - Welcome

Mr. Martin Neumeyer, Director General of the State Minister for Federal and European Affairs in the Bavarian State Chancellery

EuropaBio's Open Day

Welcome & Keynote Speech - Introduction

Dr Hans Kast, EuropaBio Chairman, President & CEO of BASF Plant Science

EuropaBio's Open Day

Welcome & Keynote Speech

Mr. Peter Mandelson, European Commissioner for External Trade

EuropaBio's Open Day

Towards a patient centred healthcare system

- Dr. Andrea Rappagliosi, EuropaBio Healthcare Council Chair, Merck Serono
- Mr. Thomas Bols, Director government affairs Amgen
- Mr. Simon Rozendaal, author of 'It's MY Life'
- Panel discussion with patient representatives, Mr. Ysbrand Poortman & Ms. Beatrice De Schepper

EuropaBio's Open Day

From Lisbon to the knowledge based bio-economy

Mr. Nicolas Denis, Associate Principal McKinsey

EuropaBio's Open Day

From Lisbon to the knowledge based bio-economy

- Mr. Nicolas Denis, Associate Principal McKinsey
- Mr. Jack Huttner, EuropaBio Industrial Biotech Council Chair, Genencor - a Danisco Division
- Dr. Bernward Garthoff, EuropaBio Agri-Food Council Chair, Bayer CropScience, DIB
- Dr. George Tzotzos, Chief Biotechnology Unit UNIDO
- Mr. Julien Mousnier, Mid-Term Review Policy Coordinator European Commission
- Panel discussion

EuropaBio's Open Day

Closing Remarks

EuropaBio Secretary General Dr. Johan Vanhemelrijck

EuropaBio's Open Day

Welcome & Keynote Speech

Mr. Patrick Wall, Chairman EFSA Management Board

EuropaBio's Open Day

Introduction

Moderator Mr. Peter O'Donnell, editor Talk About Europe

EuropaBio's Open Day

Style Debate

The UK House of Commons format

Mr. Etienne VERVAECKE, General Commissioner Eurobio 2007 and 2009

EuroBio 2007 edition : A clear acceleration in the development of the event

Mr. Etienne VERVAECKE, CEO Gie EURASANTE

Huge investment in the biotech and nutrition sector in Lille confirms this cluster's attractiveness

Ms. Martine LEMAIRE, Senior Director Scientific & Business Development - PORSOLT & PARTNERS PHARMACOLOGY

Announcement : Services in animal pharmacology for almost 20 years

Mr. Philippe FORNIES, CEO GENAXION

Announcement: Genaxion is a global sales organization focused on biotech, pharmaceuticals, cosmetic, diagnostics and chemical market

Mr. Stuart Mc Keen, Ministry of research and Innovation, Ontario

Ontario's looking for collaboration for companies with France and Europe

Mr. François Lescure, Chairman MidiBiotech & Montserrat VENDRELL, CEO BioRegion of Catalonia

Save the date : December 3rd and 4th Location: Toulouse For the first Euro Region Biotech and Healthcare Meeting held by MIdiBIotech and the Region of Catalunya

Mr. Pierre Nokin, Managing Director Biowin

Health Cluster of Wallonia short presentation

Johan Vanhemelrijck, Europabio

Presents the EuropaBio strategy for the coming months

« If you want to be part of the discussion with the EMEA, join EuropaBio! »